More recently, Bierie and colleagues used ITGB4 as a functional biomarker to classify more aggressive CSCs from other mesenchymal carcinoma cell subsets in triple-negative breast cancer [25]. This evidence concerns the gene ITGB4 and triple-negative breast carcinoma.